JAK-STAT signaling in the therapeutic landscape of myeloproliferative neoplasms

Molecular and Cellular Endocrinology

Volumn 451, Issue , 2017, Pages 71-79

  O'Sullivan, Jennifer M ^a   Harrison, Claire N ^a  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

JAK inhibitor; JAK STAT; Myeloproliferative neoplasm; Primary myelofibrosis; Ruxolitinib

Indexed keywords

AZACITIDINE; CALRETICULIN; DANAZOL; FEDRATINIB; JANUS KINASE; LENALIDOMIDE; MOMELOTINIB; PACRITINIB; PANOBINOSTAT; PLACEBO; RUXOLITINIB; STAT PROTEIN; ANTINEOPLASTIC AGENT; CALRETICULIN, HUMAN; JAK2 PROTEIN, HUMAN; JANUS KINASE 2; MPL PROTEIN, HUMAN; PYRAZOLE DERIVATIVE; THROMBOPOIETIN RECEPTOR;

ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; DIARRHEA; DRUG APPROVAL; DRUG EFFICACY; DRUG WITHDRAWAL; HUMAN; MYELOID METAPLASIA; MYELOPROLIFERATIVE NEOPLASM; NAUSEA AND VOMITING; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POLYCYTHEMIA VERA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; SIGNAL TRANSDUCTION; SOMATIC MUTATION; THROMBOCYTOPENIA; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; WEIGHT GAIN; WERNICKE ENCEPHALOPATHY; BONE MARROW CELL; CELL PROLIFERATION; CELL SURVIVAL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HEMATOLOGIC DISEASE; METABOLISM; MOLECULARLY TARGETED THERAPY; MYELOPROLIFERATIVE DISORDER; PATHOLOGY;

ANTINEOPLASTIC AGENTS; CALRETICULIN; CELL PROLIFERATION; CELL SURVIVAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HEMATOLOGIC NEOPLASMS; HUMANS; JANUS KINASE 2; MOLECULAR TARGETED THERAPY; MYELOID CELLS; MYELOPROLIFERATIVE DISORDERS; PYRAZOLES; RECEPTORS, THROMBOPOIETIN; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS;

EID: 85012885394     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2017.01.050     Document Type: Article

References (74)

1. Abdelrahman, R.A., Begna, K.H., Al-Kali, A., et al. Momelotinib treatment-emergent neuropathy: prevalence, risk factors and outcome in 100 patients with myelofibrosis. Br. J. Haematol. 169 (2015), 77–80.
2. Arber, D.A., Orazi, A., Hasserjian, R., et al. The 2016 Revision to the World Health Organization Classification of Myeloid Neoplasms and Acute Leukemia Blood, vol 127, 2016, 2391–2405.
3. Baerlocher, G.M., Oppliger Leibundgut, E., Ottmann, O.G., et al. Telomerase inhibitor imetelstat in patients with essential thrombocythemia. N. Engl. J. Med. 373 (2015), 920–928.
4. Barbui, T., Thiele, J., Passamonti, F., et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J. Clin. Oncol. 29 (2011), 3179–3184.
5. Beer, P., Campbell, P.J., Scott, L., et al. MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood 112 (2008), 141–149.
6. Bose, P., Verstovsek, S., Investigational histone deacetylase inhibitors (HDACi) in myeloproliferative neoplasms. Expert Opin. Investig. Drugs 25 (2016), 1393–1403.
7. Breccia, Massimo, Molica, Matteo, Colafigli, Gioia, Alimena, Giuliana, Improvement of bone marrow fibrosis with ruxolitinib: will this finding change our perception of the drug?. Expert Rev. Hematol. 8:4 (2015), 387–389.
8. Brunold, C., Braschler, T.R., Go, N., et al. Imetelstat, a potent telomerase inhibitor, inhibits the spontaneous growth of CFU-Meg in vitro from essential thrombocythemia patients but not from healthy individuals. Presented at the 53rd American Society of Hematology Annual Meeting, San Diego, CA, December 10–13, 2011 (abstract).
9. Cabagnols, X., Defour, J.P., Ugo, V., et al. Differential association of calreticulin type 1 and type 2 mutations with myelofibrosis and essential thrombocythemia: relevance for disease evolution. Leukemia 29 (2015), 249–252.
10. Cabagnols, X., Favale, F., Pasquier, F., et al. Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients. Blood 127 (2016), 333–342.
11. Cerquozzi, S., Tefferi, A., Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors. Blood Cancer J., 5, 2015, 366.
12. Cervantes, F., Dupriez, B., Pereira, A., et al. New prognostic scoring system for primary myelofibrosis based on a study of the international working group for myelofibrosis research and treatment. Blood 113 (2009), 2895–2901.
13. Cervantes, F., Vannucchi, A.M., Kiladjian, J.J., et al. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood 122 (2013), 4047–4053.
14. Chachoua, I., Pecquet, El-Khoury M., et al. Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants. Blood 127 (2016), 1325–1335.
15. Daver, N., Garcia-Manero, G., Cortes, J.E., et al. 5-Azacytidine (AZA) in combination with ruxolitinib (RUX) as therapy for patients (pts) with myelodysplastic/myeloproliferative neoplasms (MDS/MPNs). Blood, 126(23), 2015, 823.
16. Delhommeau, F., Dupont, S., Della Valle, V., et al. Mutation in TET2 in myeloid cancers. N. Engl. J. Med. 360 (2009), 2289–2301.
17. Ding, J., Komatsu, H., Wakita, A., et al. Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin. Blood 103 (2004), 4198–4200.
18. Drexler, B., Passweg, J.R., Bigler, M., et al. Effects of the sympathicomimetic agonist mirabegron on disease course, mutant allele burden, marrow fibrosis, and nestin positive stem cell niche in patients with JAK2-mutated myeloproliferative neoplasms: a prospective multicenter phase II trial SAKK 33/14. Blood, 2016 (ASH abstract), Poster 3108.
19. Elf, S., Abdelfattah, N.S., Chen, E., et al. Mutant calreticulin requires both its mutant C-terminus and the thrombopoietin receptor for oncogenic transformation. Cancer Discov. 6 (2016), 368–381.
20. Finazzi, G., Vannucchi, A., Martinelli, V., et al. A phase II study of Givinostat in combination with hydroxycarbamide in patients with polycythaemia vera unresponsive to hydroxycarbamide monotherapy. Br. J. Haematol. 161 (2013), 688–694.
21. Rampal, R., Al-Shahrour, F., Abdel-Wahab, O., et al. Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis. Blood 123 (2014), 123–132.
22. Gilead Announces Top-Line Results from Two Phase 2 Studies Evaluating Momelotinib for Patients With Myelofibrosis. http://www.businesswire.com/news/home/20161116006411/en/.
23. Gisslinger, H., Klade, C., Georgiev, P., et al. Final Results from PROUD-PV a Randomised Controlled Phase 3 Trial Comparing Ropeginterferon to Hydroxyurea in Polycythaemia Vera Patients. ASTRACT. Oral ASH, 2016.
24. Gotlib, J., Gupta, V., Roberts, A.W., et al. Update on the long-term efficacy and safety of momelotinib, a JAK1 and JAK2 inhibitor, for the treatment of myelofibrosis. Blood, 122, 2013, 108.
25. Gowin, K.L., Kosiorek, H.E., Dueck, A.C., et al. Final analysis of a multicenter pilot phase 2 study of ruxolitinib and danazol in patients with myelofibrosis. Blood, 126, 2015, 1618.
26. Guglielmelli, P., Biamonte, F., Rotunno, G., et al. COMFORT-II Investigators; Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative (AGIMM) Investigators. Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study. Blood 123 (2014), 2157–2160.
27. Harrison, C., Kiladjian, J.J., Al-Ali, H.K., et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N. Engl. J. Med. 366 (2012), 787–798.
28. Harrison, C.N., Kiladjian, J.-J., Heidel, F.H., et al. Efficacy, safety, and confirmation of the recommended phase 2 starting dose of the combination of ruxolitinib (rux) and panobinostat (PAN) in patients (pts) with myelofibrosis (MF). Blood, 126, 2015, 4060.
29. Harrison, C.N., Mead, A., Panchal, A., et al. Ruxolitinib compared with best available therapy for Essential Thrombocythaemia patients resistant or intolerant to hydroxycarbamide in MAJIC - an investigator lead randomised trial. EHA Annu. Meet. Abstr. Haematol., 101(101S), 2016, 93.
30. Heine, A., Brossart, P., Wolf, D., Ruxolinitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis?. Blood, 2013, 122.
31. CTI BioPharma Announces Removal of Full Clinical Hold on Pacritinib http://www.prnewswire.com/news-releases/cti-biopharma-announces-removal-of-full-clinical-hold-on-pacritinib-300386115.html.
32. CTI BioPharma Provides Update On Investigational Agent Pacritinb. http://www.prnewswire.com/news-releases/cti-biopharma-provides-update-on-investigational-agent-pacritinib-300216412.html.
33. James, C., Ugo, V., Le Couedic, J.P., et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434 (2005), 1144–1148.
34. Kiladjian, J.J., Cassinat, B., Chevret, S., et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood 112 (2008), 3065–3072.
35. Kiladjian, J.J., Chomienne, C., Fenaux, P., Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms. Leukaemia 22 (2008), 1990–1998.
36. Klampfl, T., Gisslinger, H., Harutyunyan, A.S., et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N. Engl. J. Med. 369 (2013), 2379–2390.
37. Kralovics, R., Passamonti, F., Buser, A.S., et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Engl. J. Med. 352 (2005), 1779–1790.
38. Lu, X., Huang, L.J., Lodish, H.F., Dimerization by a cytokine receptor is necessary for constitutive activation of JAK2V617F. J. Biol. Chem. 283 (2008), 5258–5266.
39. Lundberg, P., Karow, A., Nienhold, R., et al. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood 123 (2014), 2220–2228.
40. Mascarenhas, J., Hoffman, R., Talpaz, M., et al. Results of the Persist-2 phase 3 study of pacritinib (PAC) versus best available therapy (BAT), including ruxolitinib (RUX), in patients (pts) with myelofibrosis (MF) and platelet counts <100,000/μl. Abstract LBA-5. Presented at the 2016 ASH Annual Meeting, December 6, 2016 (San Diego, California).
41. Mead, A., Clark, R., Chacko, J., et al. Response to ruxolitinib in patients with intermediate-1, intermediate-2 and high-risk myelofibrosis: results of the UK Robust trial. Br. J. Haematol. 170 (2015), 29–39.
42. Mesa, R.A., Li, C.Y., Ketterling, R.P., et al. Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood 105 (2005), 973–977.
43. Mesa, R., Miklos, E., et al. Results of the PERSIST-1 phase III study of pacritinib (PAC) versus best available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia-myelofibrosis (PET-MF). J. Clin. Oncol., 33, 2015 (suppl; abstr LBA7006).
44. Mikkelsen, S.U., Kjær, L., Skov, V., et al. Safety and efficacy of combination therapy of interferon-alpha2 + JAK1-2 inhibitor in the philadelphia-negative chronic myeloproliferative neoplasms. Preliminary results from the danish combi-trial - an open label, single arm, non-randomized multicenter phase II study. Blood, 126, 2015, 824.
45. Milosevic Feenstra, J.D., Nivarthi, H., Gisslinger, H., et al. Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms. Blood 127 (2016), 325–332.
46. Nangalia, J., Massie, C.E., Baxter, E.J., et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N. Engl. J. Med. 369 (2013), 2391–2405.
47. Oh, S.T., Simonds, E.F., Jones, C., et al. Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. Blood 116 (2010), 988–992.
48. Pardanani, A., Levine, R., Lasho, T., et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 108 (2006), 3472–3476.
49. Pardanani, A., Harrison, C., Cortes, J.E., et al. Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial. JAMA Oncol. 1 (2015), 643–651.
50. Passamonti, F., Kiladjian, J.-J., Vannucchi, A.M., et al. ReTHINK: a randomized, double-blind, placebo-controlled, multicenter, phase 3 study of ruxolitinib in early myelofibrosis patients. ASCO Meet. Abstr.(15_Suppl. l), 2016, 34 TPS7080.
51. Passamonti, F., Griesshammer, M., Palandri, F., et al. Ruxolitinib Proves Superior to Best Available Therapy in Patients with Polycythemia Vera (PV) and a Nonpalpable Spleen: Results from the Phase IIIb RESPONSE-2 Study. Abstract #S112, 2016, 21st Congress of the European Hematology Association (EHA), Copenhagen, Denmark.
52. Pencik, J., Thanh Pham, H.T., Schmoelleri, J., et al. JAK-STAT signaling in cancer: from cytokines to non-coding genome. Cytokine 87 (2016), 26–36.
53. Pietra, D., Rumi, E., Ferretti, V.V., et al. Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms. Leukaemia 30 (2016), 431–438.
54. Pikman, Y., Lee, B.H., Mercher, T., et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med., 3(7), 2006, e270.
55. Scott, L.M., Tong, W., Levine, R.L., et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N. Engl. J. Med. 356 (2007), 459–468.
56. Silver, R.T., Vandris, K., Goldman, J.J., Recombinant interferon-alpha may retard progression of early primary myelofibrosis: a preliminary report. Blood 117 (2011), 6669–6672.
57. Stegelmann, F., Bangerter, M., Heidel, F.H., et al. A phase-ib/II study of ruxolitinib plus pomalidomide in myelofibrosis. Blood, 126, 2015, 826.
58. Tefferi, A., Jimma, T., Sulai, N.H., et al. IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F. Leukemia vol 24 (2010), 1128–1138.
59. Tefferi, A., Rumi, E., Finazzi, G., et al. Survival and Prognosis Among 1263 Patients with Polycythemia Vera: an International Study. Blood (ASH Annual Meeting Abstracts). 2011 Abstract 277.
60. Tefferi, A., Lasho, T.L., Begna, K.H., et al. A pilot study of the telomerase inhibitor imetelstat for myelofibrosis. N. Engl. J. Med. 373 (2015), 908–919.
61. Teofili, L., Martini, M., Cenci, T., et al. Different STAT-3 and STAT-5 phosphorylation discriminates among Ph-negative chronic myeloproliferative diseases and is independent of the V617F JAK-2 mutation. Blood 110 (2007), 354–359.
62. Teofili, L., Giona, F., Martini, M., et al. Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia. J. Clin. Oncol. 25 (2007), 1048–1053.
63. Vainchenker, W., Delhommeau, F., Constantinescu, S.N., Bernard, O.A., New mutations and pathogenesis of myeloproliferative neoplasms. Blood 118 (2011), 1723–1735.
64. Vannucchi, A.M., Antonioli, E., Guglielmelli, P., et al. Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia. Blood 112 (2008), 844–847.
65. Vannucchi, A.M., Kiladjian, J.J., Griesshammer, M., et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N. Engl. J. Med. 372 (2015), 426–435.
66. Verma, A., Deb, D.K., Sassano, A., et al. Activation of the p38 mitogen-activated protein kinase mediates the suppressive effects of type 1 interferons and transforming growth factor-beta on normal haematopoiesis. J. Biol. Chem. 277 (2002), 7726–7735.
67. Verstovesek, S., Kantarjian, H., et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N. Engl. J. Med. 363 (2010), 1117–1127.
68. Verstovsek, S., Mesa, R.A., Gotlib, J., et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N. Engl. J. Med. 366 (2012), 799–807.
69. Verstovsek, S., Mesa, R.A., et al. Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I. Haematologica 100 (April 2015), 479–488.
70. Verstovsek, S., Vannucchi, A.M., Griesshammer, M., et al. Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial. Haematologica 101 (2016), 821–829.
71. Walz, C., Ahmed, W., Lazarides, K., et al. Essential role for Stat5a/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2(V617F) in mice. Blood 119 (2012), 3550–3560.
72. Wang, W.A., Groenendyk, J., Michalak, M., Calreticulin signaling in health and disease. Int. J. Biochem. Cell Biol. 44 (2012), 842–846.
73. Yan, D., Hutchison, R.E., Mohi, G., Critical requirement for Stat5 in a mouse model of polycythemia vera. Blood 119 (2012), 3539–3549.
74. Zhang, Q., Zhang, Y., Diamond, S., et al. The Janus kinase 2 inhibitor fedratinib inhibits thiamine uptake: a putative mechanism for the onset of Wernicke's encephalopathy. Drug Metabolism Dispos. 42 (2014), 1656–1662.